CROI 2019 Abstract eBook

Abstract eBook

Keyword Index

Network models 873, 1092 Neural tube 743 Neural tube defect 430, 745 NeuroAIDS 425, 453, 1012 Neurocognition 426, 449, 516, 821 Neurocognitive disorder 419, 420, 425 Neurocognitive impairment 124, 129, 409, 411, 414, 418, 420, 424, 434, 449, 453, 454, 516, 703, 823 Neurocognitive performance 128, 422, 426, 445 NeuroHIV 412, 415, 417, 446, 449 Neuroimaging 442, 455, 458, 822 Neuroinflammation 125, 126, 435, 460 Neuronal injury 454 Neuropathogenesis 125, 126, 415, 429, 431, 433, 446 Neuropsychiatric adverse events 440 Neuropsychologic performance 412, 440, 455, 1069 Neuropsychological assessment 441, 442 Neuropsychological testing performance 421, 444 Neuropsychology 413 Neurosyphilis 1012, 1013, 1014 Neurotoxicity 401, 419 Neutralization 166, 357, 358 Neutralizing antibodies 204, 309 Nevirapine 825 Nevirapine prophylaxis 792 Next generation sequencing (NGS) 542, 595, 876 NFkB 22 NHBS 972 Nicaragua 940 NKG2D 365 NMR-based lipoprotein profile 243 Non Communicable Diseases (NCDs) 660, 677 632, 658, 1063, 1064 Non-AIDS defining cancer 291, 1072 Non-AIDS events 224, 253, 258, 287, 1064 Non-AIDS mortality 410, 649 Non-Hodgkin lymphoma 317 Non-human primate model 24, 137, 223, 475 Non-nucleoside reverse transcriptase inhibitors 530 Nonnucleoside reverse transcriptase inhibitor (NNRTI) 746 Non–AIDS-defining cancers 16 Northern South Africa 269 Northern Uganda 838 Non-Occupational Post-Exposure Prophylaxis (nPEP) 984 NRTI 419, 789 NRTIs backbone 547 NRTIs resistance mutations 547 Nuclear envelope 72 Nuclear import 72, 73, 186 Nucleocapsid 74 Nucleoside reverse transcriptase inhibitors 530 Nugent score 1000 Nurse-based care 536 Nutrition 42, 791 OAT1/OAT3 470 OATP1B1 468 Obesity 129, 230, 384, 677, 795, 1069 Observational cohort study 505, 693, 883 Obstructive lung disease 1070 Neurodevelopment 42, 784, 785, 786 Neurofilament light chain 127, 421, 454

Partner testing 926, 930, 1005 Pathogenesis 223, 250 Patient management 151 Patient tracing 1030 PBPK 470, 487, 827 PCSK9 567, 650 PD-1 27, 131, 132, 208, 351 PD-L1 291 PD1 335 Pediatric ART 798, 805, 826, 829 Pediatric HIV 809, 816, 820 People living with HIV 426, 577, 1063 People who inject drugs (PWID) 561, 582, 593, 601, 834, 871, 883, 886, 887, 888, 891, 892 Perinatal 821 Perinatal HIV infection 45, 752, 762, 769, 776, 788, 796, 806, 811, 812, 816, 819, 820 Perinatal infection 807 Peripheral blood 347 Peripheral blood mononuclear cells (PBMCs) 316, 477 PET imaging 460 Phage display 310 Pharmacodynamics 471 Pharmacogenetics 52, 471, 472, 1010 Pharmacokinetics 51, 78, 103, 141, 419, 443, 467, 471, 473, 476, 478, 487, 758, 759, 826, 827, 829, 830, 1010 Phase 2a 142 Phenotype susceptibility 532 Phenotypic resistance 143, 548, 549, 550 Phylodynamics 591, 592, 593, 594, 856, 862, 872, 888 Phylogenetic clustering 592, 597, 861, 863, 864, 867, 871 Phylogenetic diversity 867 Phylogenetics 23, 342, 375, 593, 856, 862, 869, 871, 877, 879, 888 Phylogeography 877, 879 Physical function 703 Pipelines 542 Placenta 322, 772 Placenta pathology 322 Plasma viremia 393 Plasmacytoid dendritic cell 198 Platelet function 639, 640 Platelets 369, 432 Pneumocystis 712 Pneumonia 713 Point of care 53, 142, 465, 554, 779, 780, 940, 947, 961, 1061 Polycomb repressor complex 2 378 Polymorphism 173 Polypharmacy 437, 466 Poor immune recovery 243 Population based HIV testing 138 Population based intervention 956, 1040 Population growth 1065 Population pharmacokinetics 757 Postal test 49 Postexposure prophylaxis (PEP) 982, 983, 984, 985 Postpartum 762, 763, 766, 767, 777, 1008 Pre-Exposure Prophylaxis (PrEP) 34, 48, 99, 100, 102, 104, 105, 106, 107, 229, 463, 473, 487, 488, 554, 598, 776, 778, 845, 850, 944, 945, 946, 947, 948, 949, 950, 955, 956, 957, 958, 959, 961, 962, 967, 968, 969, 971, 972, 974, 977, 979, 980, 981, 982, 986, 987, 988, 989, 991, 992, 993, 994, 995, 996, 997, 1077, 1082, 1083, 1085 • Awareness of 972, 975, 978 • Barriers to 976 • Continuum 973, 987 • Discontinuation of 963, 990, 993 Peripheral T follicular helper cells 265 Persistence 23, 106, 125, 338, 798, 805 Persistent immunodeficiency 211 Peru 529, 841

Pregnant and breastfeeding women 764, 774, 776, 1082 Pregnant women 39, 87, 321, 586, 629, 755, 760, 765, 926, 928, 980, 1003 Pretreatment drug resistance 527 Prevalence 605, 1067, 848 Prevention 79, 723, 835, 953, 956, 994, 1087 Prevention impact 768, 1087 Prevention-of-mother-to child transmission (PMTCT) 40, 45, 744, 764, 768, 774, 790, 1007 Primary care 587 Primary effusion lymphoma 17 Primary HIV infection 299, 523, 867 Probiotic 35, 206, 228 Prognostic model 288 Program access 840 Progressive multifocal leukoencephalopathy 448 Proliferation 313 Prophylaxis 628, 712 Prostate cancer 1072 Protease cleavage site 294 Protease inhibitors 176, 451, 495, 675, 746, 756 Primary prevention 775 Prisoners 839, 1020, 1053 Prisons 839, 1020 PRO140 486

Protein kinase C agonist 369 Protein-protein interaction 70 Proteomic profile 261 Providers 895 Proviral DNA 348, 543, 544, 806 PSA screening 1072 Psychiatric disorders 700 Public Health 807, 1005 Pulmonary disease 15, 661, 795 Pulmonary embolism 637 Pulmonary function 661 Pulmonary hypertension 659 Purinergic 187 qPCR 614 QTc interval 84

Quality assurance 559 Quality of life 496, 697

Quantification 558 QVOA 135, 333, 362 Race 893, 1089 Raltegravir 39, 471, 533, 745, 760 Random forest 913 Randomized controlled trial 14, 92, 136, 145, 299, 1031 Randomized open-label trial 1025

Randomized trial 1018 Rapamycin 131, 352, 386 Rapid start 514, 515 Reactivated HIV reservoir virus 358 Reactivation 373 Real-life cohort 493, 503, 987

Real-time adherence monitoring 1046 Rebound virus 309, 349, 391, 392, 402 Recency of HIV infection 831, 939, 940, 941, 942 Recombinants 169, 869 Record linkage 818 Rectal 402 Rectal infection 970 Rectal viral shedding 524 Reengagement in care 896, 1031 Remission 804 Renal function 519, 566, 693 Renal impairment 506 Renal tubular disease 691 Repeat testing 775, 777, 778 Repeated measures 1042 Replication-competent reservoir 136, 339, 380 Reproductive health 998

Keyword Index

Occupational exposure 984 Ocular complications 855 Older HIV-infected subjects 502 On demand PrEP 960 Oncogenesis 19 Opioid agonist therapy 561, 953 Opioid monitoring 889 Opioid use 147, 618, 883, 889, 953 Opportunistic infection 707 Option B+ 754 Oral mucosa 213 Oraquick 782 Osteoporosis 686, 687, 689 Otosyphilis 1013 Ototoxicity 740 Outbreak 857 Outcomes 504, 521 Overdose 883 Oxidative stress 429, 430 P-TEFb 175 P2X 187 Parathyroid hormone 688 Partner notification 930, 1005 Partner services 930, 954

• Eligibility 845, 961, 971 • Interest 835, 974, 978 • Persistence 944, 947, 963, 993 • Stigma 988

Reservoir 22, 23, 125, 133, 169, 323, 327, 338, 344, 345, 346, 347, 352, 356, 375, 380, 382, 391, 394, 395, 399, 432, 448, 475, 491, 610, 614, 726, 800, 804 Reservoir mapping 326 Reservoir persistence 387 Resident memory T cells 345 Residual HIV viremia 265 Residual RNA 249, 558 Residual viremia 380, 491 Resistance 305, 507, 532, 546, 551, 595, 738, 907, 966

Prediction 105 Predictive model 740 Predictors 698

Predictors of mortality 711 Preexisting resistance 552 Preferences 935, 1054 Pregancy outcome 746, 753, 755, 756 Pregnancy 40, 47, 321, 322, 586, 589, 745, 747, 750, 755, 757, 758, 759, 762, 767, 773, 775, 777, 778, 1003, 1006, 1086 Pregnancy intention 1006, 1008

Resistance associated variants 182, 600 Resistance mutations 451, 540, 541, 611 Resource limited settings 496, 499, 518

CROI 2019 463